{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:32:55Z","timestamp":1792783975898,"version":"4.5.0"},"reference-count":135,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":69,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian","award":["201807111"],"award-info":[{"award-number":["201807111"]}]},{"name":"Clinical Medicine Center Construction Program of Fuzhou, Fujian","award":["2018080309"],"award-info":[{"award-number":["2018080309"]}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.csbj.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:07:41Z","timestamp":1558606061000},"page":"661-674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":464,"title":["Application of PD-1 Blockade in Cancer Immunotherapy"],"prefix":"10.34133","volume":"17","author":[{"given":"Xiaomo","family":"Wu","sequence":"first","affiliation":[{"name":"Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China"},{"name":"Department of Biomedicine, University of Basel, Klingelbergstr. 70, CH-4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkai","family":"Gu","sequence":"additional","affiliation":[{"name":"The Institute of Biomedical Sciences, Fudan University, Mingdao Building, Dongan Road 131, Shanghai 200032, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borui","family":"Chen","sequence":"additional","affiliation":[{"name":"Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou 350005, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Weng","sequence":"additional","affiliation":[{"name":"Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[{"name":"The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Xihong Road 312, Fuzhou 350025, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the knowledge of sarcoma","volume":"14","author":"Coley W.B.I.I.","year":"1891","unstructured":"Coley W.B.I.I.: Contribution to the knowledge of sarcoma. Ann Surg 1891; 14: 199.","journal-title":"Ann Surg"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0818-9641.2003.01151.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer; a biological approach. I. the processes of control","volume":"1","author":"Burnet M.","year":"1957","unstructured":"Burnet M.: Cancer; a biological approach. I. the processes of control. Br Med J 1957; 1: 779.","journal-title":"Br Med J"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05610"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2018.03.033"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.003"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05919.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082492"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm955"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505497102"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm863"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.8.4919"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3259"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00666.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)80025-4"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270825"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.5.2342"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601347103"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali E.N.","year":"2012","unstructured":"Rozali E.N., Hato S.V., Robinson B.W., Lake R.A. and Lesterhuis W.J.: Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012; 2012: 656340.","journal-title":"Clin Dev Immunol"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","author":"Ribas A.","year":"2018","unstructured":"Ribas A. and Wolchok J.D.: Cancer immunotherapy using checkpoint blockade. Science 359, 2018, 1350-1355; .","journal-title":"Science"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes A.","year":"2016","unstructured":"Younes A., Santoro A., Shipp M., Zinzani P.L., Timmerman J.M. et al: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtho.2016.08.110","article-title":"P2.39: Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy","volume":"11","author":"Ramalingam S.","year":"2016","unstructured":"Ramalingam S., Hui R., Gandhi L., Carcereny E., Felip E. et al: P2.39: Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy. J. Thor. Oncol. 2016; 11: S241.","journal-title":"J. Thor. Oncol."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R.","year":"2017","unstructured":"Chen R., Zinzani P.L., Fanale M.A., Armand P., Johnson N.A. et al: Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017; 35: 2125.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka Y.","year":"2015","unstructured":"Asaoka Y., Ijichi H. and Koike K.: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 373: 1979.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1510353"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs C.S.","year":"2018","unstructured":"Fuchs C.S., Doi T., Jang R.W., Muro K., Satoh T. et al: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018; 4: e180013.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6795"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2147\/DDDT.S162214","article-title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","volume":"12","author":"Yang H.","year":"2018","unstructured":"Yang H., Shen K., Zhu C., Li Q., Zhao Y. et al: Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des Devel Ther 2018; 12: 2085.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","first-page":"S1032","DOI":"10.21037\/jtd.2018.04.61","article-title":"Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer","volume":"10","author":"Tomasini P.","year":"2018","unstructured":"Tomasini P., Greillier L., Boyer A., Jeanson A. and Barlesi F.: Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. J Thorac Dis 2018; 10: S1032.","journal-title":"J Thorac Dis"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.09.008"},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai Y.","year":"2017","unstructured":"Iwai Y., Hamanishi J., Chamoto K. and Honjo T.: Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24.","journal-title":"J Biomed Sci"},{"key":"e_1_3_2_85_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima T.F.","year":"2017","unstructured":"Nishijima T.F., Shachar S.S., Nyrop K.A. and Muss H.B.: Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 2017; 22: 470.","journal-title":"Oncologist"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong J.","year":"2018","unstructured":"Gong J., Chehrazi-Raffle A., Reddi S. and Salgia R.: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018; 6.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu Y.B.","year":"2017","unstructured":"Hu Y.B., Zhang Q., Li H.J., Michot J.M., Liu H.B. et al: Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Trans Lung Cancer Res 2017; 6: S8.","journal-title":"Trans Lung Cancer Res"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman C.F.","year":"2016","unstructured":"Friedman C.F., Proverbs-Singh T.A. and Postow M.A.: Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2: 1346.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2017.11.024","article-title":"Re: safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"199","author":"Chang S.S.","year":"2018","unstructured":"Chang S.S.: Re: safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Urol 2018; 199: 341.","journal-title":"J Urol"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"e_1_3_2_93_2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv069","article-title":"Checkpoint blockade immunotherapy for cancer comes of age","volume":"107","author":"Brower V.","year":"2015","unstructured":"Brower V.: Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst 2015; 107.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176822","article-title":"Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis","volume":"12","author":"Zhao T.","year":"2017","unstructured":"Zhao T., Li C., Wu Y., Li B. and Zhang B.: Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS One 2017; 12: e0176822.","journal-title":"PLoS One"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25187"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2015.65.1067","article-title":"Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels","volume":"34","author":"Stadler Z.K.","year":"2016","unstructured":"Stadler Z.K., Battaglin F., Middha S., Hechtman J.F., Tran C. et al: Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol 2016; 34: 2141.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11312"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0110"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"E7769","DOI":"10.1073\/pnas.1607836113","article-title":"Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors","volume":"113","author":"Danilova L.","year":"2016","unstructured":"Danilova L., Wang H., Sunshine J., Kaunitz G.J., Cottrell T.R. et al: Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A 2016; 113: E7769.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_104_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","article-title":"BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma","volume":"3","author":"Bradley S.D.","year":"2015","unstructured":"Bradley S.D., Chen Z., Melendez B., Talukder A., Khalili J.S. et al: BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol Res 2015; 3: 602.","journal-title":"Cancer Immunol Res"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F"},{"key":"e_1_3_2_106_2","first-page":"1275","article-title":"Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes","volume":"24","author":"Seliger B.","year":"1996","unstructured":"Seliger B., Harders C., Wollscheid U., Staege M.S., Reske-Kunz A.B. et al: Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 1996; 24: 1275.","journal-title":"Exp Hematol"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0143"},{"key":"e_1_3_2_109_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12916-016-0705-4","article-title":"Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set","volume":"14","author":"Roszik J.","year":"2016","unstructured":"Roszik J., Haydu L.E., Hess K.R., Oba J., Joon A.Y. et al: Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 2016; 14: 168.","journal-title":"BMC Med"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.434"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.11.007"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646710"},{"key":"e_1_3_2_113_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3349\/ymj.2017.58.5.1031","article-title":"Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4(+)CD25(+)FoxP3(+) regulatory T-cells and induced by TGF-beta1 and IL-10","volume":"58","author":"Hong J.W.","year":"2017","unstructured":"Hong J.W., Lim J.H., Chung C.J., Kang T.J., Kim T.Y. et al: Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4(+)CD25(+)FoxP3(+) regulatory T-cells and induced by TGF-beta1 and IL-10. Yonsei Med J 2017; 58: 1031.","journal-title":"Yonsei Med J"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2008.08.284"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009"},{"key":"e_1_3_2_116_2","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1002\/jcp.26075","article-title":"Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis","volume":"233","author":"Safarzadeh E.","year":"2018","unstructured":"Safarzadeh E., Orangi M., Mohammadi H., Babaie F. and Baradaran B.: Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis. J Cell Physiol 2018; 233: 3024.","journal-title":"J Cell Physiol"},{"key":"e_1_3_2_117_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00262-017-2088-6","article-title":"Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model","volume":"67","author":"Namdar A.","year":"2018","unstructured":"Namdar A., Mirzaei R., Memarnejadian A., Boghosian R., Samadi M. et al: Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model. Cancer Immunol Immunother 2018; 67: 367.","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_3_2_118_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00005-017-0492-4","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives","volume":"66","author":"Ibanez-Vea M.","year":"2018","unstructured":"Ibanez-Vea M., Zuazo M., Gato M., Arasanz H., Fernandez-Hinojal G. et al: Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives. Arch Immunol Ther Exp (Warsz) 2018; 66: 113.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"E318","DOI":"10.1111\/hepr.12260","article-title":"Novel therapeutic target of hepatocellular carcinoma by manipulation of macrophage colony-stimulating factor\/tumor-associated macrophages axis in tumor microenvironment","volume":"44","author":"Zhou D.","year":"2014","unstructured":"Zhou D., Huang C., Kong L. and Li J.: Novel therapeutic target of hepatocellular carcinoma by manipulation of macrophage colony-stimulating factor\/tumor-associated macrophages axis in tumor microenvironment. Hepatol Res 2014; 44: E318.","journal-title":"Hepatol Res"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031670"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15520"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1938"},{"key":"e_1_3_2_123_2","doi-asserted-by":"crossref","first-page":"e1802","DOI":"10.1038\/cddis.2015.150","article-title":"LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer","volume":"6","author":"Liu Y.W.","year":"2015","unstructured":"Liu Y.W., Sun M., Xia R., Zhang E.B., Liu X.H. et al: LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis 2015; 6: e1802.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240537"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240527"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.009"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6918"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z"},{"key":"e_1_3_2_130_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CJI.0000000000000122","article-title":"Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines","volume":"39","author":"Liu J.","year":"2016","unstructured":"Liu J., Zhang S., Hu Y., Yang Z., Li J. et al: Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines. J Immunother 2016; 39: 171.","journal-title":"J Immunother"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.131"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.005"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.12.005"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3965"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003777963"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037018302526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037018302526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2019.03.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:58:55Z","timestamp":1778014735000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2019.03.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":135,"alternative-id":["10.1016\/j.csbj.2019.03.006"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2019.03.006","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of PD-1 Blockade in Cancer Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}